| scholarly article | Q13442814 |
| P50 | author | Hernando A del Portillo Obando | Q64682462 |
| Luiz Hildebrando Pereira da Silva | Q18216350 | ||
| Erney P Camargo | Q40532482 | ||
| Carmen Fernandez Becerra | Q42761148 | ||
| P2093 | author name string | Paulo Afonso Nogueira | |
| Fabiana Piovesan Alves | |||
| Neida Rodrigues Santos | |||
| Oliver Pein | |||
| P2860 | cites work | High prevalence of asymptomatic Plasmodium vivax and Plasmodium falciparum infections in native Amazonian populations | Q47911926 |
| Human migration and the spread of malaria in Brazil | Q47995648 | ||
| Epitopes in the 19kDa fragment of the Plasmodium falciparum major merozoite surface protein-1 (PfMSP-1(19)) recognized by human antibodies | Q47999588 | ||
| Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese vi | Q48000659 | ||
| IgG isotype to C-terminal 19 kDa of Plasmodium vivax merozoite surface protein 1 among subjects with different levels of exposure to malaria in Brazil | Q48004892 | ||
| Characterization of naturally acquired human IgG responses against the N-terminal region of the merozoite surface protein 1 of Plasmodium vivax | Q48012867 | ||
| Economic and social consequences of malaria in new colonization projects in Brazil | Q48017781 | ||
| Detection and identification of the four malaria parasite species infecting humans by PCR amplification. | Q48030204 | ||
| Antigenicity of recombinant proteins derived from Plasmodium falciparum merozoite surface protein 1. | Q48036521 | ||
| Levels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanaian children are not associated with protection from clinical malaria. | Q33866742 | ||
| A longitudinal study of human antibody responses to Plasmodium falciparum rhoptry-associated protein 1 in a region of seasonal and unstable malaria transmission | Q34001155 | ||
| Plasmodium vivax malaria vaccine development | Q34462082 | ||
| Towards a blood-stage vaccine for malaria: are we following all the leads? | Q34572160 | ||
| Repeat sequences in block 2 of Plasmodium falciparum merozoite surface protein 1 are targets of antibodies associated with protection from malaria | Q34855814 | ||
| Humoral immune responses of Solomon Islanders to the merozoite surface antigen 2 of Plasmodium falciparum show pronounced skewing towards antibodies of the immunoglobulin G3 subclass | Q35544545 | ||
| Acquired immune responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1 in individuals exposed to malaria | Q35546112 | ||
| Cross-species regulation of Plasmodium parasitaemia cross-examined | Q35775447 | ||
| Maintenance of serum antibody levels | Q36072426 | ||
| Fine specificity of serum antibodies to Plasmodium falciparum merozoite surface protein, PfMSP-1(19), predicts protection from malaria infection and high-density parasitemia | Q36576319 | ||
| Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity | Q36943252 | ||
| Primary structure of the merozoite surface antigen 1 of Plasmodium vivax reveals sequences conserved between different Plasmodium species | Q37506803 | ||
| Antibodies to the N-terminal block 2 of plasmodium falciparum merozoite surface protein 1 are associated with protection against clinical malaria | Q37582802 | ||
| A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses | Q38952180 | ||
| Seasonal Malaria Transmission and Variation of Anopheline Density in Two Distinct Endemic Areas in Brazilian Amazônia | Q39023347 | ||
| A longitudinal study of naturally acquired cellular and humoral immune responses to a merozoite surface protein (MSP1) of Plasmodium falciparum in an area of seasonal malaria transmission. | Q39387268 | ||
| Differential patterns of human immunoglobulin G subclass responses to distinct regions of a single protein, the merozoite surface protein 1 of Plasmodium falciparum | Q39518517 | ||
| Human antibody response to Plasmodium falciparum merozoite surface protein 2 is serogroup specific and predominantly of the immunoglobulin G3 subclass | Q39823427 | ||
| Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages | Q41835030 | ||
| Surface antigens of malaria merozoites. A high molecular weight precursor is processed to an 83,000 mol wt form expressed on the surface of Plasmodium falciparum merozoites | Q41971716 | ||
| Longitudinal study of naturally acquired humoral immune responses against the merozoite surface protein 1 of Plasmodium vivax in patients from Rondonia, Brazil | Q43498253 | ||
| Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. | Q46334562 | ||
| Antibody response to the N and C-terminal regions of the Plasmodium vivax Merozoite Surface Protein 1 in individuals living in an area of exclusive transmission of P. vivax malaria in the north of Brazil | Q47842676 | ||
| Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro | Q47845842 | ||
| Symptomless Plasmodium vivax infections in native Amazonians | Q47846859 | ||
| Infrequency of asymptomatic malaria in an endemic area in Amazonas, Brazil | Q47906832 | ||
| Association of the IgG response to Plasmodium falciparum merozoite protein (C-terminal 19 kD) with clinical immunity to malaria in the Brazilian Amazon region | Q47911253 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | malaria | Q12156 |
| antibody | Q79460 | ||
| Plasmodium vivax | Q311376 | ||
| P304 | page(s) | 2726-2733 | |
| P577 | publication date | 2006-05-01 | |
| P1433 | published in | Infection and Immunity | Q6029193 |
| P1476 | title | A reduced risk of infection with Plasmodium vivax and clinical protection against malaria are associated with antibodies against the N terminus but not the C terminus of merozoite surface protein 1. | |
| P478 | volume | 74 |
| Q90606530 | A simple, ex vivo phagocytosis assay of Plasmodium vivax merozoites by flow cytometry |
| Q37685993 | A systematic review on malaria sero-epidemiology studies in the Brazilian Amazon: insights into immunological markers for exposure and protection |
| Q28750566 | Acquired antibody responses against Plasmodium vivax infection vary with host genotype for duffy antigen receptor for chemokines (DARC) |
| Q37419309 | Allele-specific antibodies to Plasmodium vivax merozoite surface protein-1: prevalence and inverse relationship to haemoglobin levels during infection. |
| Q36845116 | Alterations of splenic architecture in malaria are induced independently of Toll-like receptors 2, 4, and 9 or MyD88 and may affect antibody affinity |
| Q41150428 | An immunomics approach for the analysis of natural antibody responses to Plasmodium vivax infection |
| Q35970236 | Antibody Profiling in Naïve and Semi-immune Individuals Experimentally Challenged with Plasmodium vivax Sporozoites |
| Q36313424 | Antigenic polymorphism and naturally acquired antibodies to Plasmodium vivax merozoite surface protein 1 in rural Amazonians |
| Q33617694 | Asymptomatic Plasmodium vivax infections induce robust IgG responses to multiple blood-stage proteins in a low-transmission region of western Thailand |
| Q34987487 | Asymptomatic infection in individuals from the municipality of Barcelos (Brazilian Amazon) is not associated with the anti-Plasmodium falciparum glycosylphosphatidylinositol antibody response |
| Q34726966 | B cell epitope mapping and characterization of naturally acquired antibodies to the Plasmodium vivax Merozoite Surface Protein-3α (PvMSP-3α) in malaria exposed individuals from Brazilian Amazon |
| Q34546246 | Evaluation of the Naturally Acquired Antibody Immune Response to the Pv200L N-terminal Fragment of Plasmodium vivax Merozoite Surface Protein-1 in Four Areas of the Amazon Region of Brazil |
| Q36560648 | Genetic diversity among Plasmodium vivax isolates along the Thai-Myanmar border of Thailand |
| Q37704962 | Genetic diversity of MSP1 Block 2 of Plasmodium vivax isolates from Manaus (central Brazilian Amazon). |
| Q37352099 | High levels of IgG3 anti ICB2-5 in Plasmodium vivax-infected individuals who did not develop symptoms |
| Q41622508 | Humoral immune responses to a recombinant Plasmodium vivax tryptophan-rich antigen among Plasmodium vivax-infected patients and its localization in the parasite |
| Q30044377 | Identification of a novel merozoite surface antigen of Plasmodium vivax, PvMSA180 |
| Q36965601 | Immunogenetic markers associated with a naturally acquired humoral immune response against an N-terminal antigen of Plasmodium vivax merozoite surface protein 1 (PvMSP-1). |
| Q38943177 | Immunogenicity and antigenicity of Plasmodium vivax merozoite surface protein 10. |
| Q34234390 | Immunological markers of Plasmodium vivax exposure and immunity: a systematic review and meta-analysis |
| Q35898819 | In silico Identification and Validation of a Linear and Naturally Immunogenic B-Cell Epitope of the Plasmodium vivax Malaria Vaccine Candidate Merozoite Surface Protein-9 |
| Q38728598 | Insights into the naturally acquired immune response to Plasmodium vivax malaria |
| Q37583147 | Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite |
| Q33532314 | Lineage-specific positive selection at the merozoite surface protein 1 (msp1) locus of Plasmodium vivax and related simian malaria parasites. |
| Q33939774 | Malaria in Brazil: an overview |
| Q37924602 | Molecular markers and genetic diversity of Plasmodium vivax |
| Q38159694 | N-terminal Plasmodium vivax merozoite surface protein-1, a potential subunit for malaria vivax vaccine |
| Q35964846 | Naturally Acquired Antibody Responses to Plasmodium vivax and Plasmodium falciparum Merozoite Surface Protein 1 (MSP1) C-Terminal 19 kDa Domains in an Area of Unstable Malaria Transmission in Southeast Asia |
| Q46926980 | Naturally Acquired Binding-Inhibitory Antibodies to Plasmodium vivax Duffy Binding Protein and Clinical Immunity to Malaria in Rural Amazonians. |
| Q35606249 | Naturally acquired humoral and cellular immune responses to Plasmodium vivax merozoite surface protein 9 in Northwestern Amazon individuals |
| Q37308698 | Naturally acquired immune responses to P. vivax merozoite surface protein 3α and merozoite surface protein 9 are associated with reduced risk of P. vivax malaria in young Papua New Guinean children |
| Q28394065 | Naturally-acquired humoral immune responses against the N- and C-termini of the Plasmodium vivax MSP1 protein in endemic regions of Brazil and Papua New Guinea using a multiplex assay |
| Q37018632 | Plasmodium vivax: who cares? |
| Q34546254 | Polymorphism of the Pv200L fragment of merozoite surface protein-1 of Plasmodium vivax in clinical isolates from the Pacific coast of Colombia |
| Q37333369 | Strain-specific duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous plasmodium vivax strains in Papua New Guinean children |
| Q48037292 | The antigenicity of a Plasmodium vivax reticulocyte binding protein-1 (PvRBP1) recombinant fragment in humans and its immunogenicity and protection studies in Aotus monkeys. |
| Q37638131 | What Is Known about the Immune Response Induced by Plasmodium vivax Malaria Vaccine Candidates? |
Search more.